Phase II Study on Combination of Capecitabine and Oxaliplatin in Patients With Relapsed or Refractory Gastric Cancer
The result of treatment in relapsed and refractory gastric cancer is still not satisfactory.
For the moment, the combination of 5-Fu and cisplatin is regularly used. Capecitabine and
Oxaliplatin are new generation drugs of 5-Fu and cisplatin. The current study is to evaluate
the efficacy and toxicity of this combination.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Jin Li, PhD
China: Ethics Committee